On Monday, Harrow earned an upgrade to its Relative Strength (RS) Rating, from 68 to 71.
Can You Really Time The Stock Market?
This exclusive rating from Investor's Business Daily tracks share price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the best-performing stocks tend to have an 80 or better RS Rating as they launch their largest climbs. See if Harrow can continue to show renewed price strength and clear that threshold.
Harrow is now considered extended and out of buy range after clearing a 20.31 buy point in a third-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
The company showed 0% EPS growth in the latest quarterly report, while sales growth came in at 38%.
Harrow holds the No. 139 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
